Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T18:12:00.803Z Has data issue: false hasContentIssue false

Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome

Published online by Cambridge University Press:  04 March 2025

Yuke Ma
Affiliation:
School of Clinical Medicine, Henan University, Kaifeng, China
Yukuan Du
Affiliation:
Department of Clinical Laboratory, Huaihe Hospital of Henan University, Kaifeng, China
Jingnan Yang
Affiliation:
Department of Clinical Laboratory, Huaihe Hospital of Henan University, Kaifeng, China
Huichao Wang
Affiliation:
Department of Nephrology, The First Affiliated Hospital of Henan University, Kaifeng, China
Xuhong Lin*
Affiliation:
Department of Clinical Laboratory, Huaihe Hospital of Henan University, Kaifeng, China
*
Corresponding author: Xuhong Lin; Email: lxh80726@126.com
Rights & Permissions [Opens in a new window]

Abstract

Objectives

The purpose of this study was to measure and examine the levels of IgG, IgM, and Spike antibody induced by inactivated vaccines, including CoronaVac and BBIBP-CorV.

Methods

Two groups of healthy adults over 18 years old (50 participants per group), who had previously received 1 dose of either BBIBP-CorV or CoronaVac and receiving either a homologous booster of BBIBP-CorV or a heterologous booster of CoronaVac. Serum IgG, IgM, and Spike antibody levels against SARS-COV-2 were measured using magnetic particle chemiluminescence immunoassay and the ELISA method.

Results

The results showed that both spike antibody and IgG/IgM antibodies elicited by a CoronaVac booster following 1 dose of BBIBP-CorV were significantly higher than those elicited by either a homologous BBIBP-CorV booster or a heterologous BBIBP-CorV booster. The Spike antibody against SARS-COV-2 induced by the heterologous CoronaVac booster reached 200.3, which is substantially greater than that induced by the homologous BBIBP-CorV booster (127.5 pg/mL). Conversely, the Spike antibody against SARS-COV-2 induced by the heterologous BBIBP-CorV booster reached 53.93 pg/mL, which is substantially greater than that induced by the homologous CoronaVac booster (9.60 pg/mL).

Conclusions

In summary, CoronaVac is immunogenic as a booster dose following 1 dose of BBIBP-CorV and is immunogenically superior to both the homologous booster and the heterologous BBIBP-CorV booster.

Information

Type
Original Research
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc
Figure 0

Figure 1.Overview of the study design and vaccination regimens used. The schematic illustrates the sequence of vaccine administration and antibody measurements.

Figure 1

Figure 2.Cartoon representation of the SARS-CoV-2 structure, highlighting key features such as the Spike protein and receptor-binding domain (RBD) that are targeted by antibodies.

Figure 2

Table 1.Demographic information of participants enrolled

Figure 3

Figure 3.(A) Average concentration of SARS-CoV-2 IgG antibodies induced by 4 types of vaccinations. (B) Comparison of SARS-CoV-2 IgM antibody levels induced by 4 types of vaccinations. (C) Average concentration of SARS-CoV-2 Spike antibody induced by 4 types of vaccinations. The data show significant differences in antibody levels between the different vaccination regimens. *p < 0.05, ****p < 0.0001.

Figure 4

Figure 4.(A-D) Comparison of SARS-CoV-2 IgG antibody concentrations between male and female participants across different vaccination groups. (E) Average concentrations of SARS-CoV-2 IgG antibodies in different age groups. The data illustrate variations in immune responses by sex and age, with statistical comparisons between groups. *p < 0.05.